Kidney stone disease

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2598-2608

  Coe, Fredric L ^a,c   Evan, Andrew ^b   Worcester, Elaine ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALLOPURINOL; CALCITRIOL; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CALCIUM SENSING RECEPTOR; CAPTOPRIL; CHLORTALIDONE; CITRATE POTASSIUM; CITRIC ACID; COLESTYRAMINE; CYSTINE; HYDROCHLOROTHIAZIDE; PENICILLAMINE; POTASSIUM; POTASSIUM MAGNESIUM CITRATE; STRUVITE; THIAZIDE DIURETIC AGENT; TIOPRONIN; UNCLASSIFIED DRUG; URATE; URATE AMMONIUM; UREASE; URIC ACID;

AGEUSIA; AUTOSOMAL DOMINANT DISORDER; BACTERIAL INFECTION; BARTTER SYNDROME; CLINICAL TRIAL; CRYSTALLIZATION; CYSTINURIA; DIETARY INTAKE; EXTRACORPOREAL LITHOTRIPSY; FAMILIAL DISEASE; FEMALE; FEVER; GENE MUTATION; GLOMERULITIS; HEMATURIA; HENLE LOOP; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY CALCIFICATION; KIDNEY TUBULE BASEMENT MEMBRANE; LASER LITHOTRIPSY; LIQUID; MALE; MONOGENIC DISORDER; NEPHROLITHIASIS; NEPHROTIC SYNDROME; PATHOGENESIS; PHASE TRANSITION; PHENOTYPE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REVIEW; RISK FACTOR; SERUM SICKNESS; SOLID; SYMPTOM; ULTRASONIC LITHOTRIPSY; URINE PH;

ANIMALS; CALCIUM OXALATE; CALCIUM PHOSPHATES; FEMALE; HUMANS; KIDNEY CALCULI; MAGNESIUM COMPOUNDS; MALE; PHARMACEUTICAL PREPARATIONS; PHOSPHATES;

EID: 26444575907     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI26662     Document Type: Review

References (123)

1. Zarse, C.A., et al. 2004. Helical computed tomography accurately reports urinary stone composition using attenuation values: in vitro verification using high-resolution micro-computed tomography calibrated to Fourier transform infrared microspectroscopy. Urology. 63:828-833.
2. Lingeman, J.E., Kim, S.C., Kuo, R.L., McAteer, J.A., and Evan, A.P. 2003. Shockwave lithotripsy: anecdotes and insights. J. Endourol. 17:687-693.
3. Bagley, D.H. 2002. Expanding role of ureteroscopy and laser lithotripsy for treatment of proximal ureteral and intrarenal calculi. Curr. Opin. Urol. 12:277-280.
4. Clayman, R.V. 2005. Percutaneous nephrolithotomy: an update [comment]. J. Urol. 173:1199.
5. Gillen, D.L., Worcester, E.M., and Coe, F.L. 2005. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int. 67:685-690.
6. Madore, F., Stampfer, M.J., Rimm, E.B., and Curhan, G.C. 1998. Nephrolithiasis and risk of hypertension. Am. J. Hypertens. 11:46-53.
7. Brown, C.M., and Purich, D.L. 1992. Physical-chemical processes in kidney stone formation. In Disorders of bone and mineral metabolism. F.L. Coe and M.J. Favus, editors. Raven Press. New York, New York, USA. 613-624.
8. Parks, J.H., Coward, M., and Coe, F.L. 1997. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 51:894-900.
9. Parks, J.H., Goldfischer, E.R., and Coe, F.L. 2003. Changes in urine volume accomplished by physicians treating nephrolithiasis. J. Urol. 169:863-866.
10. Asplin, J.R., Parks, J.H., and Coe, F.L. 1997. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int. 52:1602-1608.
11. Asplin, J.R., Parks, J.H., Nakagawa, Y., and Coe, F.L. 2002. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 61:1821-1829.
12. Coe, F.L., and Parks, J.H. 2000. Pathogenesis and treatment of nephrolithiasis. In The kidney. D. Seldin and G. Giebisch, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 1841-1867.
13. Coe, F.L., Parks, J.H., and Nakagawa, Y.N. 2002. Inhibitors and promoters of calcium oxalate crystallization: their relationship to the pathogenesis of nephrolithiasis. In Disorders of bone and mineral metabolism. F.L. Coe and M.J. Favus, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania. 741-775.
14. Asplin, J.R., Arsenault, D., Parks, J.H., Coe, F.L., and Hoyer, J.R. 1998. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 53:194-199.
15. Stapleton, A.M., and Ryall, R.L. 1995. Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Br. J. Urol. 75:712-719.
16. Marengo, S.R., Resnick, M.I., Yang, L., and Churchill, P.C. 1998. Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men. J. Urol. 159:1444-1450.
17. Pillay, S.N., Asplin, J.R., and Coe, F.L. 1998. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am. J. Physiol. 275:F255-F261.
18. Hess, B., Nakagawa, Y., Parks, J.H., and Coe, F.L. 1991. Molecular abnormality of Tamm Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am. J. Physiol. 29:F569-F578.
19. Evan, A.P., et al. 2003. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111:607-616. doi:10.1172/JCI200317038.
20. Kim, S.C., et al. 2005. Stone formation is proportional to papillary surface coverage by Randall's plaque. J. Urol. 173:117-119.
21. Evan, A.P., et al. 2005. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int. 68:145-154.
22. Sheng, X., Jung, T., Wesson, J.A., and Ward, M.D. 2005. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc. Natl. Acad. Sci. U. S. A. 102:267-272.
23. Kuo, R.L., et al. 2003. Urine calcium and volume predict coverage of renal papilla by Randall's plaque. Kidney Int. 64:2150-2154.
24. Marshall, R.W., Cochran, M., and Hodgkinson, A. 1972. Relationships between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal-stone-forming subjects. Clin. Sci. 43:91-99.
25. Lemann, J., Jr., Worcester, E.M., and Gray, R.W. 1991. Hypercalciuria and stones [review]. Am. J. Kidney Dis. 17:386-391.
26. Parks, J.H., and Coe, F.L. 1986. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int. 30:85-90.
27. Curhan, G.C., Willett, W.C., Speizer, F.E., and Stampfer, M.J. 2001. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 59:2290-2298.
28. Favus, M.J., Karnauskas, A.J., Parks, J.H., and Coe, F.L. 2004. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J. Clin. Endocrinol. Metab. 89:4937-4943.
29. Lemann, J., Jr., Lennon, E.J., Piering, W.F., Prien, E.L., Jr., and Ricanati, E.S. 1970. Evidence that glucose ingestion inhibits net renal tubular reabsorption of calcium and magnesium in man. J. Lab. Clin. Med. 75:578-585.
30. Breslau, N.A., Sakhaee, K., and Pak, C.Y. 1985. Impaired adaptation to salt-induced urinary calcium losses in postmenopausal osteoporosis. Trans. Assoc. Am. Physicians. 98:107-115.
31. Hess, B.; Ackermann, D., Essig, M., Takkinen, R., and Jaeger, P. 1995. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J. Clin. Endocrinol. Metab. 80:1916-1921.
32. Borghi, L., et al. 2002. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N. Engl. J. Med. 346:77-84.
33. Asplin, J.R., et al. 2003. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 63:662-669.
34. Coe, F.L., Parks, J.H., Bushinsky, D.A., Langman, C.B., and Favus, M.J. 1988. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 33:1140-1146.
35. Gambaro, G., et al. 2004. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am. J. Kidney Dis. 44:963-986.
36. Moe, D.W., and Bonny, O. 2005. Genetic hypercalciuria. J. Am. Soc. Nephrol. 16:729-745.
37. Thakker, R.V. 2000. Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int. 57:787-793.
38. Gunther, W., Luchow, A., Cluzeaud, F., Vandewalle, A., and Jentsch, T.J. 1998. ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc. Natl. Acad. Sci. U. S. A. 95:8075-8080.
39. Luyckx, V.A., et al. 1998. Intrarenal and subcellular localization of rat CLC5. Am. J. Physiol. 275:F761-F769.
40. Reinhart, S.C., et al. 1994. Characterization of carrier females and affected males with x-linked recessive nephrolithiasis. J. Am. Soc. Nephrol. 5:S54-S58.
41. Nakazato, H., et al. 1997. Mutations in the CLCN5 gene in Japanese patients with familial idiopathic low-molecular-weight proteinuria. Kidney Int. 52:895-900.
42. Scheinman, S.J. 1998. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int. 53:3-17.
43. Raja, K.A., et al. 2002. Responsiveness of hypercalciuria to thiazide in Dent's disease. J. Am. Soc. Nephrol. 13:2938-2944.
44. Hoopes, R.R., Jr., et al. 2004. Evidence for genetic heterogeneity in Dent's disease. Kidney Int. 65:1615-1620.
45. Scheinman, S.J., et al. 2000. Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int. 57:232-239.
46. Wang, S.S., et al. 2000. Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum. Mol. Genet. 9:2937-2945.
47. Silva, I.V., et al. 2003. The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J. Bone Miner. Res. 18:615-623.
48. Gunther, W., Piwon, N., and Jentsch, T.J. 2003. The ClC-5 chloride channel knock-out mouse - an animal model for Dent's disease. Pflugers Arch. 445:456-462.
49. Naesens, M., Steels, P., Verberckmoes, R., Vanrenterghem, Y., and Kuypers, D. 2004. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol. 96:65-78.
50. Taugner, R., et al. 1988. The juxtaglomerular apparatus in Bartter's syndrome and related tubulopathies. An immunocytochemical and electron microscopic study. Virchows Arch. A. Pathol. Anat. Histol. 412:459-470.
51. Pope, J.C., et al. 1996. The natural history of nephrocalcinosis in premature infants treated with loop diuretics. J. Urol. 156:709-712.
52. Brown, E.M., Pollak, M., and Hebert, S.C. 1998. The extracellular calcium-sensing receptor: its role in health and disease. Annu. Rev. Med. 49:15-29.
53. Ba, J., and Friedman, P.A. 2004. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium. 35:229-237.
54. Hebert, S.C., Brown, E.M., and Harris, H.W. 1997. Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J. Exp. Biol. 200:295-302.
55. Pearce, S.H., et al. 1996. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335:1115-1122.
56. Okazaki, R., et al. 1999. A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. 84:363-366.
57. Yamamoto, M., Akatsu, T., Nagase, T., and Ogata, E. 2000. Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85:4583-4591.
58. Carling, T., et al. 2000. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85:2042-2047.
59. Watanabe, S., et al. 2002. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet. 360:692-694.
60. Vargas-Poussou, R., et al. 2002. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J. Am. Soc. Nephrol. 13:2259-2266.
61. Muller, D., et al. 2003. A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am. J. Hum. Genet. 73:1293-1301.
62. Weber, S., et al. 2000. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis maps to chromosome 3q27 and is associated with mutations in the PCLN-1 gene. Eur. J. Hum. Genet. 8:414-422.
63. Weber, S., et al. 2001. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J. Am. Soc. Nephrol. 12:1872-1881.
64. Reed, B.Y., Heller, H.J., Gitomer, W.L., and Pak, C.Y. 1999. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J. Clin. Endocrinol. Metab. 84:3907-3913.
65. Reed, B.Y., et al. 2002. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J. Clin. Endocrinol. Metab. 87:1476-1485.
66. Geng, W., et al. 2005. Cloning and characterization of the human soluble adenylyl cyclase. Am. J. Physiol. Cell Physiol. 288:C1305-C1316.
67. Heller, H.J., and Pak, C.Y.C. 2002. Primary hyperparathyroidism. In Disorders of bone and mineral metabolism. F.L. Coe and M.J. Favus, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 516-534.
68. Pak, C.Y., et al. 2004. Rapid communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney Int. 66:2032-2037.
69. Parks, J.H., Worcester, E.M., O'Connor, R.C., and Coe, F.L. 2003. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 63:255-265.
70. von Unruh, G.E., Voss, S., Sauerbruch, T., and Hesse, A. 2004. Dependence of oxalate absorption on the daily calcium intake. J. Am. Soc. Nephrol. 15:1567-1573.
71. Holmes, R.P., Goodman, H.O., and Assimos, D.G. 2001. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 59:270-276.
72. Bataille, P., Presne, C., and Fournier, A. 2002. Prevention of recurrent stones in idiopathic hypercalciuria. N. Engl. J. Med. 346:1667-1669.
73. Baggio, B., et al. 1993. Evidence of a link between erythrocyte band 3 phosphorylation and anion transport in patients with 'idiopathic' calcium oxalate nephrolithiasis. Miner. Electrolyte Metab. 19:17-20.
74. Baggio, B., et al. 1986. An inheritable anomaly of red-cell oxalate transport in "primary" calcium nephrolithiasis correctable with diuretics. N. Engl. J. Med. 314:599-604.
75. Dobbins, J.W., and Binder, H.J. 1997. Importance of the colon in enteric hyperoxaluria. N. Engl. J. Med. 296:298-301.
76. Worcester, E.M. 2002. Stones from bowel disease. Endocrinol. Metab. Clin. North Am. 31:979-999.
77. Danpure, C.J., and Rumsby, G. 2004. Molecular aetiology of primary hyperoxaluria and its implications for clinical management. Expert Rev. Mol. Med. 2004:1-16.
78. Asplin, J.R. 2002. Hyperoxaluric calcium nephrolithiasis. Endocrinol. Metab. Clin. North Am. 31:927-949.
79. Milliner, D.S., et al. 1994. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N. Engl. J. Med. 331:1553-1558.
80. Jamieson, N.V. 1998. The results of combined liver/kidney transplantation for primary hyperoxaluria (PH1) 1984-1997. The European PH1 transplant registry report. European PH1 Transplantation Study Group. J. Nephrol. 11(Suppl. 1):36-41.
81. Brennan, S., Hering-Smith, K., and Hamm, L.L. 1988. Effect of pH on citrate reabsorption in the proximal convoluted tubule. Am. J. Physiol. 255:F301-F306.
82. Sakhaee, K., et al. 1993. Alkali absorption and citrate excretion in calcium nephrolithiasis. J. Bone Miner. Res. 8:789-794.
83. Donnelly, S., Kamel, K.S., Vasuvattakul, S., Narins, R.G., and Halperin, M.L. 1992. Might distal renal tubular acidosis be a proximal tubular cell disorder? Am. J. Kidney Dis. 19:272-281.
84. Pak, C.Y., et al. 1985. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am. J. Med. 79:284-288.
85. Lemann, J., Jr., Pleuss, J.A., Gray, R.W., and Hoffmann, R.G. 1991. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults. Kidney Int. 39:973-983.
86. Lemann, J., Jr., Gray, R.W., and Pleuss, J.A. 1989. Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. Kidney Int. 35:688-695.
87. Grover, P.K., Ryall, R.L., and Marshall, V.R. 1990. Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis. Clin. Sci. (Lond.). 79:9-15.
88. Grover, P.K., Ryall, R.L., Potezny, N., and Marshall, V.R. 1990. The effect of decreasing the concentration of urinary urate on the crystallization of calcium oxalate in undiluted human urine. J. Urol. 143:1057-1061.
89. Grover, P.K., Ryall, R.G., and Marshall, V.R. 1992. Calcium oxalate crystallization in urine: role of urate and glycosaminoglycans. Kidney Int. 41:149-154.
90. Mandel, N.S., and Mandel, G.S. 1989. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J. Urol. 142:1516-1521.
91. Klee, L.W., Brito, C.G., and Lingeman, J.E. 1991. The clinical implications of brushite calculi. J. Urol. 145:715-718.
92. Evan, A.P., et al. 2005. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 67:576-591.
93. Parks, J.H., Worcester, E.M., Coe, F.L., Evan, A.P., and Lingeman, J.E. 2004. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 66:777-785.
94. Carlisle, E.J., Donnelly, S.M., and Halperin, M.L. 1991. Renal tubular acidosis (RTA): recognize the ammonium defect and pHorget the urine pH. Pediatr. Nephrol. 5:242-248.
95. DuBose, T.D., Jr. 2004. Acid-base disorders. In The kidney. B.M. Brenner, editor. Saunders. Philadelphia, Pennsylvania, USA. 922-996.
96. Karet, F.E., et al. 1998. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc. Natl. Acad. Sci. U. S. A. 95:6337-6342.
97. Devonald, M.A., Smith, A.N., Poon, J.P., Ihrke, G., and Karet, F.E. 2003. Non-polarized targeting of AE1 causes autosomal dominant distal renal tubular acidosis. Nat. Genet. 33:125-127.
98. Quilty, J.A., Cordat, E., and Reithmeier, R.A. 2002. Impaired trafficking of human kidney anion exchanger (kAE1) caused by hetero-oligomer formation with a truncated mutant associated with distal renal tubular acidosis. Biochem. J. 368:895-903.
99. Karet, F.E., et al. 1999. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat. Genet. 21:84-90.
100. Stehberger, P.A., et al. 2003. Localization and regulation of the ATP6V0A4 (a4) vacuolar H+-ATPase subunit defective in an inherited form of distal renal tubular acidosis. J. Am. Soc. Nephrol. 14:3027-3038.
101. Shah, G.N., Bonapace, G., Hu, P.Y., Strisciuglio, P., and Sly, W.S. 2004. Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation. Hum. Mutat. 24:272.
102. Cohen, E.P., et al. 1992. Absence of H+ ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J. Am. Soc. Nephrol. 3:264-271.
103. Ahlstrand, C., and Tiselius, H.G. 1987. Urine composition and stone formation during treatment with acetazolamide. Scand. J. Urol. Nephrol. 21:225-228.
104. Gault, M.H., et al. 1991. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine. 70:345-358.
105. Osther, P.J., Bollerslev, J., Hansen, A.B., Engel, K., and Kildeberg, P. 1993. Pathophysiology of incomplete renal tubular acidosis in recurrent renal stone formers: evidence of disturbed calcium, bone and citrate metabolism. Urol. Res. 21:169-173.
106. Sakhaee, K., Adams-Huet, B., Moe, O.W., and Pak, C.Y. 2002. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 62:971-979.
107. Pak, C.Y., Sakhaee, K., Peterson, R.D., Poindexter, J.R., and Frawley, W.H. 2001. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 60:757-761.
108. Abate, N., Chandalia, M., Cabo-Chan, A.V., Jr., Moe, O.W., and Sakhaee, K. 2004. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 65:386-392.
109. Maalouf, N.M., et al. 2004. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 65:1422-1425.
110. Palacin, M., et al. 2005. The genetics of heteromeric amino acid transporters. Physiology (Bethesda). 20:112-124.
111. Font-Llitjos, M., et al. 2005. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J. Med. Genet. 42:58-68.
112. Nakagawa, Y., Asplin, J.R., Goldfarb, D.S., Parks, J.H., and Coe, F.L. 2000. Clinical use of cystine supersaturation measurements. J. Urol. 164:1481-1485.
113. Coe, F.L., Clark, C., Parks, J.H., and Asplin, J.R. 2001. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J. Urol. 166:688-693.
114. Shekarriz, B., and Stoller, M.L. 2002. Cystinuria and other noncalcareous calculi. Endocrinol. Metab. Clin. North Am. 31:951-977.
115. Barcelo, P., Wuhl, O., Servitge, E., Rousaud, A., and Pak, C.Y. 1993. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J. Urol. 150:1761-1764.
116. Ettinger, B., et al. 1997. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 158:2069-2073.
117. Hofbauer, J., Hobarth, K., Szabo, N., and Marberger, M. 1994. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis - a prospective randomized study. Br. J. Urol. 73:362-365.
118. Ettinger, B., Citron, J.T., Livermore, B., and Dolman, L.I. 1988. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J. Urol. 139:679-684.
119. Laerum, E., and Larsen, S. 1984. Thiazide prophylaxis of urolithiasis: a double-blind study in general practice. Acta Med. Scand. 215:383-389.
120. Borghi, L., Meschi, T., Guerra, A., and Novarini, A. 1993. Randomized prospective study of a non-thiazide diuretic, indapamide, in preventing calcium stone recurrences. J. Cardiovasc. Pharmacol. 22(Suppl. 6):S78-S86.
121. Ettinger, B., Tang, A., Citron, J.T., Livermore, B., and Williams, T. 1986. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N. Engl. J. Med. 315:1386-1389.
122. Borghi, L., et al. 1996. Urinary volume, water and recurrences of idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J. Urol. 155:839-843.
123. Evan, A.P., Coe, F.L., Lingeman, J.E., and Worcester, E. 2005. Insights on the pathology of kidney stone formation. Urol. Res. doi:10.1007/s00240-005- 0488-0.